Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2021-10-27 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
2021年第三季度报告提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (475 characters) titled '2021 年第三季度报告提示性公告' which translates to '2021 Third Quarter Report Preliminary Announcement'. It states that the full third quarter report was approved and is available on the official disclosure website. The text does not contain the actual financial data or detailed report content but rather informs investors about the availability of the full quarterly report elsewhere. According to the 'MENU VS MEAL' rule, this is an announcement about the report publication, not the report itself. Therefore, the correct classification is Report Publication Announcement (RPA).
2021-10-27 Chinese
关于变更公司财务总监的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the change of the company's financial director, including the resignation of the previous financial director and the appointment of a new one. It contains no financial statements or detailed financial data, nor does it discuss financial results or performance. The content focuses on management changes, specifically at the senior management level. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report or a report publication announcement.
2021-09-30 Chinese
康芝药业独立董事关于第五届董事会第十八会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from the independent directors of 康芝药业股份有限公司 regarding proposals at the 18th meeting of the 5th board of directors. It discusses the nomination and election procedures for the financial director candidate, compliance with company law and regulations, and the qualifications of the candidate. There is no financial data, no report or results announcement, and no indication of a general meeting or shareholder vote results. The document is a governance-related statement about board procedures and director nominations, fitting best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or certification, so it is not RPA or RNS. Therefore, the classification is MANG with high confidence.
2021-09-30 Chinese
康芝药业第五届董事会第十八次会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement from Kangzhi Pharmaceutical Co., Ltd. regarding a resolution passed at the 18th meeting of the 5th Board of Directors. It details the resignation of the current CFO and the appointment of a new CFO, including the new CFO's resume and qualifications. The document includes voting results and compliance with company law and regulations. There are no financial statements or detailed financial data presented, nor is this a full report or earnings release. This is a typical Board/Management Information announcement about changes in senior management positions.
2021-09-30 Chinese
关于注射用苏拉明钠获得新药临床试验许可的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a new clinical trial license for a drug (注射用苏拉明钠) by the National Medical Products Administration (国家药品监督管理局). It details the drug's clinical trial status, regulatory approvals, and potential impact on the company. The document is relatively short (1750 characters) and serves as a formal public disclosure of regulatory progress rather than a financial report or detailed clinical study. It does not contain financial statements, earnings data, or management discussion. It is an official announcement about regulatory approval and clinical trial status, fitting best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories like Annual Report, Earnings Release, or Legal Proceedings.
2021-09-02 Chinese
独立董事关于第五届董事会第十七次会议相关事项的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent directors' opinion on matters related to the company's 2021 semi-annual report and related issues such as external guarantees and use of raised funds. It references the 2021 half-year period (January 1 to June 30, 2021) and discusses compliance with regulatory requirements. The document is not the semi-annual report itself but an independent opinion on the report and related matters, which is typical for audit or independent director opinions accompanying interim reports. The document length is 1855 characters, which is relatively short and focused on independent opinions rather than full financial statements or management discussion. Therefore, it fits best under Audit Report / Information (AR) as it provides independent directors' opinions on the half-year report and related compliance issues, rather than being the full interim report (IR) or a simple announcement (RPA). H1 2021
2021-08-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.